In last trading session, Abbott Laboratories (NYSE:ABT) saw 6.7 million shares changing hands with its beta currently measuring 0.72. Company’s recent per share price level of $119.39 trading at $1.5 or 1.27% at ring of the bell on the day assigns it a market valuation of $207.73B. That closing price of ABT’s stock is at a discount of -1.88% from its 52-week high price of $121.64 and is indicating a premium of 23.24% from its 52-week low price of $91.64. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 5.0 million shares which gives us an average trading volume of 5.75 million if we extend that period to 3-months.
For Abbott Laboratories (ABT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.76. Splitting up the data highlights that, out of 13 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 12 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 1.34 in the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Abbott Laboratories (NYSE:ABT) trade information
Upright in the green during last session for gaining 1.27%, in the last five days ABT remained trading in the green while hitting it’s week-highest on Friday, 10/18/24 when the stock touched $119.39 price level, adding 0.38% to its value on the day. Abbott Laboratories’s shares saw a change of 8.47% in year-to-date performance and have moved 2.82% in past 5-day. Abbott Laboratories (NYSE:ABT) showed a performance of 4.59% in past 30-days. Number of shares sold short was 11.83 million shares which calculate 2.44 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 128 to the stock, which implies a rise of 6.73% to its current value. Analysts have been projecting 50 as a low price target for the stock while placing it at a high target of 150. It follows that stock’s current price would jump 58.12% in reaching the projected high whereas dropping to the targeted low would mean a gain of 58.12% for stock’s current value.
Abbott Laboratories (ABT) estimates and forecasts
Statistics highlight that Abbott Laboratories is scoring comparatively lower than the scores of other players of the relevant industry. The company added 11.29% of value to its shares in past 6 months, showing an annual growth rate of 5.18% while that of industry is 11.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 4.60% from the last financial year’s standing.
20 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 11.03B for the same. And 14 analysts are in estimates of company making revenue of 10.67B in the next quarter. Company posted 10.24B and 9.96B of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 19.65% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 5.31% while estimates for its earnings growth in next 5 years are of 9.12%.
ABT Dividends
Abbott Laboratories is more likely to be releasing its next quarterly report on 2025-Jan-22 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt. With an annual yield of 1.84%, the share has a forward dividend of 2.20 which implies that company’s dividend yield remained growing in trailing twelve months while having a 5 year average dividend yield of 1.64%.
Abbott Laboratories (NYSE:ABT)’s Major holders
Insiders are in possession of 0.53% of company’s total shares while institution are holding 79.57 percent of that, with stock having share float percentage of 79.99%. Investors also watch the number of corporate investors in a company very closely, which is 79.57% institutions for Abbott Laboratories that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at ABT for having 166.35 million shares of worth $17.29 billion. And as of 2024-06-30, it was holding 9.5932 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 131.13 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.5619 of outstanding shares, having a total worth of $13.63 billion.
